Legal Representation
Attorney
Monte L. Falcoff/Jessica S. Sachs
USPTO Deadlines
Next Deadline
In Grace Period
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20191203)
Due Date
December 03, 2025
Grace Period Ends
June 03, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
43 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 3, 2024 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... |
| May 4, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Apr 27, 2021 | CORN | I | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | Loading... |
| Apr 9, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Apr 3, 2021 | CRCV | M | CORRECTION TRANSACTION RECEIVED FROM IB | Loading... |
| Mar 5, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| May 29, 2020 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Mar 21, 2020 | XXSS | O | GENERIC MADRID TRANSACTION SENT TO IB | Loading... |
| Mar 21, 2020 | XXCR | P | GENERIC MADRID TRANSACTION CREATED | Loading... |
| Mar 3, 2020 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Dec 3, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Sep 19, 2019 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Sep 17, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 17, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 28, 2019 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Aug 28, 2019 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Aug 28, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 9, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Aug 1, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 1, 2019 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 1, 2019 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 1, 2019 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 1, 2019 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jan 30, 2019 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
| Jan 25, 2019 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Jan 9, 2019 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Jan 9, 2019 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Jul 30, 2018 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
| Jan 30, 2018 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Jan 30, 2018 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Jan 30, 2018 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Jan 25, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 25, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 25, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 25, 2017 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Aug 10, 2017 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Aug 10, 2017 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Aug 9, 2017 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Aug 8, 2017 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 8, 2017 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Aug 4, 2017 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 4, 2017 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 3, 2017 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 042
Scientific and technological services, namely, laboratory research relating to the design of new pharmaceutical products and therapeutic protein-based medicines for others; design and development of new pharmaceutical products and therapeutic protein-based medicines for others utilizing recombinant DNA technologies; consulting services in the fields of pharmaceutical research and development, including therapeutic protein-based pharmaceutical research and development, and laboratory testing, diagnostics and pharmacogenetics related thereto; engineering; scientific laboratory services utilizing computer software platforms and recombinant DNA technologies for the development and optimization of pharmaceutical products, including therapeutic protein-based medicines, and laboratory analysis and laboratory research related thereto
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"TECHNOLOGY"